The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under
supportive conditions to adult participants with BP-II, current episode depressed, in
improving depressive symptoms.